MOA-728

Phase 3Small molecule

BBausch Health Americas, Inc.

MOA-728 is one of 12 small molecule programs targeting Ventral Hernia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ventral HerniaActive, not recruiting

Ventral HerniaPhase 3

Active, not recruiting

Competition

Competitive Landscape

16 competitors in Ventral Hernia

#DrugCompanyPhaseTrials

Marcaine

IInnocoll

Approved

1 2

Robaxin

GGrupo Espanol de Tumores Neuroendocrinos

Approved

1 3

Xylocaine

CCitius Pharmaceuticals, Inc.

Phase 3

1 4

Botox

VVitae Pharmaceuticals Inc., an Allergan affiliate

Phase 2

1 5

MOA-728

BBausch Health Americas, Inc.

Phase 3

1 6

AGN-151607-DP

AbbVie

Phase 2

1 7

Entereg

Merck & Co.

Preclinical

1 8

CA-008

CConcentric Analgesics

Phase 2

1 9

BOTOX Dose B

AbbVie

Phase 2

1 10

Naropin

FFresenius Kabi Oncology Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Methadone4 trials

Study Evaluating Oral MOA-728 in Subjects on Methadone Therapy

Withdrawn·BBausch Health Americas, Inc.·Phase 1·NCT00505583

Comparisons Of The Bioavailability And Pharmacodynamics Of Various Formulations Of MOA-728 In Subjects On Methadone

Completed·BBausch Health Americas, Inc.·Phase 1·NCT00398502

Dose Ranging Study in Healthy Methadone Maintenance Subjects

Completed·BBausch Health Americas, Inc.·Phase 1·NCT00387491·16 enrolled

Show 1 more trial

Study Evaluating MOA-728 in Subjects on Stable Methadone Maintenance

Completed·BBausch Health Americas, Inc.·Phase 1·NCT00447811

Treatment2 trials

Study Evaluating Oral MOA-728 for the Treatment of Opioid-Induced Bowel Dysfunction (OIBD) in Subjects With Chronic Non-Malignant Pain

Completed·BBausch Health Americas, Inc.·Phase 2·NCT00366431·420 enrolled

Study Evaluating MOA-728 Oral for the Treatment of OIBD in Subjects With Chronic Non-Malignant Pain

Completed·BBausch Health Americas, Inc.·Phase 2·NCT00605644·128 enrolled

Double-blind1 trial

Double-Blind, Double-Dummy, 2-Period Crossover of a 20-Minute Versus a 4-hour IV of MOA-728 in Stable Methadone Subjects

Completed·BBausch Health Americas, Inc.·Phase 1·NCT00444158·24 enrolled

Cardiac Repolarization1 trial

Study Evaluating the Effects of MOA-728 on Cardiac Repolarization in Healthy Subjects

Completed·BBausch Health Americas, Inc.·Phase 1·NCT00434395

Ventral Hernia1 trial

A Study Evaluating Intravenous (IV) MOA-728 for the Treatment of Postoperative Ileus (POI) in Participants After Ventral Hernia Repair

Completed·BBausch Health Americas, Inc.·Phase 3·NCT00528970·374 enrolled

3 more indications

Intravenous1 trial

Study Evaluating the Safety and Tolerability of a New Intravenous Formulation of MOA-728 in Healthy Subjects

Completed·BBausch Health Americas, Inc.·Phase 1·NCT00464802·36 enrolled

Oral1 trial

Study Evaluating the Safety of MOA-728 Administered Orally to Healthy Subjects

Completed·BBausch Health Americas, Inc.·Phase 1·NCT00311350·48 enrolled

Unspecified2 trials

Study Evaluating MOA-728 Administered in Healthy Men

Withdrawn·BBausch Health Americas, Inc.·Phase 1·NCT00427258

Bioequivalence Study in Healthy Volunteers

Completed·BBausch Health Americas, Inc.·Phase 1·NCT00387985

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for MOA-728. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MOA-728 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MOA-728. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bausch Health Americas, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: BBausch Health Americas, Inc.

MOA-728

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Methadone4 trials

Treatment2 trials

Double-blind1 trial

Cardiac Repolarization1 trial

Ventral Hernia1 trial

Intravenous1 trial

Oral1 trial

Unspecified2 trials

References

Drug Info

Quick Facts

Related News